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ABSTRACT
Patients with a submicroscopic deletion at 1q43q44 present with intellectual disability (ID), 
microcephaly,  craniofacial  anomalies,  seizures,  limb  anomalies  and  corpus  callosum 
abnormalities.  However,  the  precise  relationship  between  most  of  deleted  genes  and  the 
clinical features in these patients still remains unclear. We studied 11 unrelated patients with 
1q44 microdeletion. We showed that the deletions occurred de novo in all patients for whom 
both parents’ DNA was available (10/11). All patients presented with moderate to severe ID, 
seizures and non-specific craniofacial anomalies. By oligoarray-based comparative genomic 
hybridization (aCGH)  covering the 1q44 region at a high resolution, we obtained a critical 
deleted region containing two coding genes - HNRNPU and FAM36A - and one non-coding 
gene -  NCRNA00201.  All  three  genes  were expressed in  different  normal  human  tissues, 
including  in  human  brain,  with  highest  expression  levels  in  the  cerebellum.  Mutational 
screening of the HNRNPU and FAM36A genes in 191 patients with unexplained isolated ID 
did not reveal any deleterious mutations while the  NCRNA00201 non-coding gene was not 
analyzed. Nine  of  the  11  patients  did  not  present  with  microcephaly  or  corpus  callosum 
abnormalities and carried a small deletion containing HNRNPU, FAM36A and NCRNA00201 
but  not  AKT3 and  ZNF238,  two centromeric  genes.  These results  suggest  that  HNRNPU, 
FAM36A and  NCRNA00201  are  not  major  genes  for  microcephaly  and  corpus  callosum 
abnormalities but are good candidates for ID and seizures.
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INTRODUCTION
Intellectual disability (ID) represents the most frequent cause of severe handicap in 
children and one of the main reasons for referral in clinical genetic practices. Causes of ID are 
extremely  heterogeneous  and  can  result  from  chromosomal  rearrangements,  monogenic 
disorders,  and/or  environmental  factors.  Despite  clinical  examination  and  extensive 
complementary investigations,  no etiology is  identified in  up to 50  of  the patients  with 
moderate  to  severe  ID  [Chelly  et  al.,  2006],  hampering  accurate  genetic  counseling  and 
clinical  follow-up.  During  these  last  years,  the  advent  of  high-resolution  microarray 
techniques allowed for the detection of increasingly smaller rearrangements in patients with 
ID. The method has greatly facilitated deciphering chromosomal disorders, enabling better 
genotype – phenotype correlations and thus the identification of new genes responsible for ID.
A number of chromosomal regions scattered through the human genome are deleted in 
patients with ID, among them the 1q43q44 region. This deletion syndrome was first described 
by De Vries et  al.  [2001]. Patients present with ID, microcephaly,  craniofacial  anomalies, 
seizures,  limb  anomalies  and  corpus  callosum  abnormalities.  However,  the  precise 
relationship between most of deleted genes and the clinical  features in these patients  still 
remains  unclear.  Three studies  have each proposed a different  smallest  region of overlap 
(SRP) for corpus callosum abnormalities. A first critical deleted region described by Boland 
et al. [2007] was 1.25 Mb in size and contained two candidate genes:  AKT3 and  ZNF238. 
Next, van Bon et al. [2008] identified a second distinct critical region of 0.36 Mb in size, 
more telomeric than the first one, and containing four different candidate genes:  Clorf100, 
ADSS,  Clorf101 and  PNAS-4.  Caliebe et  al.  [2010] proposed a third interval  of 0.44 Mb, 
which is more telomeric than the other two, and which contained the HNRNPU gene. Finally, 
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the combined data from two recent studies, a first one performed on 22 patients [Ballif et al.,  
2011]  and  a  second  one  based  on  7  patients  [Nagamani  et  al.,  2012] sharing  1q43q44 
microdeletion, proposed three distinct SRO with different sizes implicated in corpus callosum 
abnormalities  (75 kb in size,  including  ZNF238),  microcephaly (133 kb in size,  including 
AKT3)  or  seizures  (100  kb  in  size,  including  HNRNPU,  FAM36A and  NCRNA00201 
previously referred as C1ORF199). We focused our study on 11 unrelated patients with ID 
and  seizures  carrying  a  1q44  interstitial  microdeletion.  We  refined  the  SRO  for  ID  and 
seizures to three genes and explored each of these three genes to highlight their potential role 
played in the phenotype.
PATIENTS AND METHODS
Patients
We  studied  11  unrelated  patients  (eight  females  and  three  males)  with  a  1q44 
microdeletion. The non-specific craniofacial anomalies are presented in Figure 1 and clinical 
features are summarized in  Table I. The patients originated from Europe (France, Sweden, 
Finland, Monaco, The Netherlands and Germany) and Senegal. No consanguinity or familial 
genetic history was noted in the families. The pregnancies were uneventful.
All patients presented with moderate to severe ID, predominantly on verbal learning 
disabilities. Milestones were delayed in all patients: sitting unsupported ranged from 6 months 
to 3 years of age, walking unsupported from 2 to 5 years of age, and severe speech delay (6 
patients aged from 4 years and 6 months to 17 years had no expressive speech and one patient 
had severe speech delay and phonetic  disorders). Neurological  examination revealed axial 
hypotonia in four cases. Five patients presented with stereotyped movements of the hands 
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with voluntary use of their  hands conserved and were suspected  for Rett  syndrome.  Two 
patients had sleep disturbances, of which one was treated with Melatonin with good results. 
Four patients had autistic features and/or attention deficit disorder.
Seizures  were observed in all  patients.  The age of the first  seizure ranged from 6 
months to 2.5 years of age. Different types of seizures were observed: absences, generalized, 
tonic-clonic  seizures  and  Lennox-Gastaut  syndrome.  Epilepsy  required  treatment  in  most 
patients,  no  pharmaco-resistant  epilepsy  was  noted  except  for  patient  3.  Two  patients 
developed status epilepticus history. Magnetic resonance imaging (MRI) revealed agenesis of 
corpus callosum in patient  2.  The corpus callosum was normal in all  other patients.  MRI 
revealed other brain abnormalities: delayed myelinisation, generalized or subcortical atrophy, 
micropolygyria, moderate ventricular dilatation and moderate cerebellar hypoplasia. Only two 
patients (#1 and # 2) among the eleven presented with microcephaly. Both patients carried the 
larger deletions including the AKT3 gene. This finding is consistent with other recent reports 
suggesting  that  AKT3  is  a  strong  candidate  gene  for  microcephaly  [Ballif  et  al.,  2011; 
Nagamani et al., 2012].
Six patients developed general obesity during childhood (BMI around +4 SD, obesity 
grade 2). Five patients had short stature (heights between -2.5 and -3 SD). Six patients had 
small hands and broad, short and/or small feet with small toes. Craniofacial anomalies were 
present in all patients, but did not lead to a characteristic facial dysmorphism. Hypertelorism 
(4/10), strabismus (4/9), bulbous nose (3/10), long and flat philtrum (5/10) and abnormal ears 
(4/10) were frequently observed.
Occasionally, some malformations were observed: unilateral renal agenesis, congenital 
heart defects (atrial septal defect and pulmonary stenosis), and some skeletal anomalies (a 
butterfly vertebrae, a scoliosis).
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Cytogenetic and aCGH studies
Informed  consent  for  genetic  analyses  was  obtained  from  parents  of  the  patients 
according to local ethical guidelines. Karyotyping  based on R or G banding was performed 
using standard methods on metaphase spreads from peripheral blood of the patients. Genomic 
DNA was extracted from peripheral blood using standard protocols. Molecular karyotyping of 
the  11  patients  was  initially  conducted  using  different  array  platforms  according  to 
manufacturers’ instructions. Subsequently, we used a custom targeted 60K Agilent array to 
fine map the breakpoints of the deletions with a median resolution of 240 bp. Custom arrays 
comprising  25,021  probes  covered  a  6  Mb  in  the  1q44  region  including  the  HNRNPU, 
FAM36A and  NCRNA00201  genes. Arrays  were analyzed with a Agilent  scanner  and the 
Feature  Extraction  software  (v.  10.5.1.1).  Graphical  overview  was  obtained  using  the 
Genomic  Workbench  software  (v.5.0).  Deletion  breakpoints  were  mapped  to  the  UCSC 
genome browser,  hg19.  A second independent  method  (fluorescence  in  situ  hybridization 
(FISH) with different probes, qPCR or MLPA) was used to confirm the deletions and for 
parental inheritance in patients for whom DNA was available. Three individuals of Yoruba 
Nigerian origin from the HapMap Project were obtained from the Coriell Institute [IHMC, 
2005] and were also analyzed using the custom 60K array.
mRNA expression studies
We performed expression analyses for  HNRNPU,  FAM36A and  NCRNA00201 using 
total RNA extracted from different human tissues (primer sequences available upon request). 
RNAs were obtained from adult brain, heart, kidney, liver, cerebellum tissues and from fetal 
brain  tissue  (Clontech).  Real  time quantitative  reverse transcription  PCR (RT-qPCR) was 
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performed using the ∆∆Ct method [Livak et al., 2001] to assess expression level of the three 
target genes - HNRNPU, FAM36A and NCRNA00201 – relative to the expression level of the 
β-actin (ACTB) and cyclophilin E (PPIE) housekeeping genes. For a given target gene, the 
∆Ct of each tissue was compared to the median of the ∆Ct of the 6 tissues analyzed.
Mutation screening
The coding exons and the exon-intron boundaries of the HNRNPU and FAM36A genes 
were sequenced in 9/11 patients with a 1q44 deletion using the Sanger technology and run on 
ABI  3130  (primer  sequences  available  upon  request).  A  series  of  191  patients  with 
unexplained isolated ID were used to search for point mutations in HNRNPU and FAM36A. 
Standard  karyotyping  was  normal  in  all  191 patients.  In  addition,  molecular  karyotyping 
performed with a 44K Agilent array was normal in 112/191 patients while the other patients 
were not analyzed. PCR amplifications followed by high-resolution melting method (HRM) 
were performed to screen  HNRNPU  (exons 2-14). PCR amplifications followed by Sanger 
sequencing were performed to screen the 5’ half of exon 1 of HNRNPU and the four exons of 
FAM36A. We failed to sequence the 3’ half of exon 1 of HNRNPU.
RESULTS
Cytogenetic and aCGH results
Following normal standard karyotyping,  a 1q44 microdeletion was identified in 11 
patients with moderate to severe ID, craniofacial anomalies and seizures using different high-
resolution array platforms. No other pathogenic genomic imbalances were identified in the 
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patients.  All  deletions  were  confirmed  by  FISH,  qPCR  or  MLPA.  Parental  analyses 
demonstrated de novo deletions in all families when both parents’ DNA was available. Using 
a custom targeted aCGH method, we showed that the sizes of the deletions were variable, 
ranging from 626 Kb to 2.57 Mb (supplementary Table I). The size of the SRO was 188 Kb 
and  encompassed  four  genes:  HNRNPU,  FAM36A,  NCRNA00201,  and  EFCAB2.  The 
identification of a normal individual with a partial deletion of the  EFCAB2 gene  led us to 
consider as unlikely causative this gene as a cause of ID, thus refining the SRO to three genes: 
HNRNPU, FAM36A, and NCRNA00201 (Fig. 2). In a previous study, Matsuzaki et al. [2009] 
identified a deletion involving HNRNPU in three HAPMAP individuals of Yoruba Nigerian 
origin.  In  contrast,  we obtained  normal  results  with  our  targeted  60K array,  excluding  a 
deletion in the 1q44 region in these individuals and, thus, demonstrating that the deletions 
identified  by  Matsuzaki  et  al.  [2009]  were  false  positive  results.  Therefore,  no  deletion 
involving one of  these three  genes  located  in  this  1q44 region has  been observed within 
individuals of the general population (www.tcag.org).
mRNA expression studies
We showed that HNRNPU, FAM36A and NCRNA00201 were expressed in 6 different 
tissues (adult brain, heart, kidney, liver, cerebellum tissues and fetal brain tissue), with the 
strongest expression in the cerebellum (Fig. 3). The highest level of transcripts was obtained 
for  NCRNA00201 in the cerebellum. As the strongest expression of theses three genes were 
detected  in  cerebellum,  we  analyzed  the  expression  of  two  control  genes:  SULF1  and 
SLCO5A1. We obtained low expression levels in the cerebellum compared to other tissues for 
these  genes,  thus  excluding  a  potential  bias  in  our  sample  of  RNA  extracted  from  the 
cerebellum (data not shown).
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Mutation screening
Direct  sequencing of  HNRNPU and  FAM36A did  not  reveal  any deleterious  point 
mutations in the remaining allele of the patients with a 1q44 deletion, rendering unlikely a 
recessive mode of inheritance. Neither did we detect any deleterious mutations in these two 
genes in our series of 191 patients with unexplained ID. Two identified exonic variants in 
HNRNPU (exon 6 c.1215G>A, synonymous; exon 14 c.2437C>G, p.Gln813Glu) and one in 
FAM36A (exon 4 c.340G>A, p.Gly114Ser) were predicted to be benign using the PolyPhen 
software.
DISCUSSION
In  this  study,  all  eleven  patients  carrying  a  1q44  microdeletion  presented  with 
moderate to severe ID, seizures and non-specific craniofacial anomalies, corresponding to a 
non-recognizable phenotype  with ID. The aCGH data allowed us to fine map  a SRO for 
moderate  to  severe ID and seizures.  However,  since other  reports  described patients  with 
deletions in the 1q43q44 bands that did not include the SRO defined in the present study, 
there may be a number of additional genes that when haploinsufficient can cause ID in these 
patients.
Two recent studies, a first one performed on 22 patients [Ballif et al., 2011] and a 
second  one  based on 7  patients  [Nagamani  et  al.,  2012]  sharing  1q43q44 microdeletion, 
clarified the phenotype/genotype correlation and proposed three distinct SRO. The first SRO 
encompassing ZNF238 was associated with corpus callosum abnormalities, the second SRO 
including  AKT3 caused microcephaly in most patients while the third SRO containing the 
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three  genes  FAM36A,  HNRNPU and  NCRNA00201  was  associated  with  seizures.  In  our 
study, 2/11 patients (#1 and # 2) carried a deletion of both ZNF238 and AKT3. Both patients 
presented with microcephaly which was consistent with a role of AKT3 in microcephaly. Only 
patient 2 presented with a corpus callosum agenesis. Incomplete penetrance associated with 
deletion  of  ZNF238  could  explain  the  lack  of  corpus  callosum abnormality  in  patient  1. 
Finally, the third previously published SRO associated with seizures in Ballif et al. [2011] 
overlapped with our 188 Kb SRO associated with ID, seizures and craniofacial anomalies.
FAM36A  encodes  a  hypothetical  protein  and,  to  date,  its  biological  role  is  still 
unknown.
HNRNPU is a protein-coding gene comprising 14 exons, which are highly conserved 
during evolution. The HNRNPU protein is able to bind RNAs and mediates different aspects 
of their metabolism and transport [Dreyfuss et al., 2002; Krecic and Swanson, 1999]. Mice 
with a homozygous hypomorphic mutation in HNRNPU are severely retarded in both growth 
and development indicating that this gene is essential for embryonic development [Roshon et 
al.,  2005].  Although  ubiquitously expressed, we detected  the  highest  expression  level  for 
HNRNPU  in  human  cerebellum,  a  tissue  which  plays  an  essential  role  in  cognition. 
Interestingly, HNRNPU is involved in later stages of differentiation of cerebellar neurons via 
the  regulation  of  DNA  topoisomerase  IIβ  activity  [Kawano  et  al.,  2010].  Thus, 
haploinsufficiency for  HNRNPU may lead  to  ID in  our  patients,  even  in  the  absence  of 
clinical cerebellar anomalies. CDH15 is such an example where a gene is strongly expressed 
in  the  cerebellum  and  mutations  for  which  are  associated  with  ID  with  no  features  of 
cerebellar dysfunction [Bhalla et al., 2008].
The third  gene within  the  SRO of  our  study,  NCRNA00201,  encodes  a  long non-
coding RNA  (lncRNA).  The majority of lncRNA has very high levels of expression in the 
central  nervous system in  a  cell-type  specific  manner,  of  which  some have already been 
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implicated in neurological and developmental disorders [for a review Qureshi et al., 2010]. It 
is  assumed  that  they  regulate  gene expression  notably  via  chromatin  remodeling  at  their 
originate locus (in cis) and/or elsewhere in the genome (in trans). This property considerably 
increases the difficulty to identify their triggers and to understand their physiological roles. 
By  RT-qPCR,  we  detected  the  highest  expression  level  for  NCRNA00201  in  human 
cerebellum,  making it  a good candidate.  Moreover,  since our three deleted  genes showed 
relatively  high  expression  in  the  cerebellum  when  compared  to  other  tissues,  we  might 
hypothesize that an epistatic effect of at least two genes from this locus could be responsible 
for our patients’ phenotype. The lack of knowledge and the difficulty to interpret the variants 
identified in a non-coding gene explain why we did not sequence NCRNA00201 in our series 
of patients with ID. NCRNA00201 still remains a good candidate to explain ID but functional 
analyses are needed to clarify the implication of this gene in the phenotype.
Taken together, our aCGH, expression and sequencing data highlight a critical region 
containing three good candidate genes for non-syndromic ID and seizures. These results will 
be important for clinicians in genetic counseling.
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LEGENDS TO FIGURES
Figure  1.  Facial  phenotypes  of  six  patients  with  interstitial  1q44  deletion  showing  non-
specific craniofacial anomalies.
Figure 2. A. Map of the deletions in chromosomal band 1q44 identified by aCGH. Black 
horizontal bars indicate the deletions in the 11 patients with ID and seizures. Grey horizontal 
bar (CNP) indicates the deletion that we have identified in a healthy individual. The RefSeq 
genes located in the genomic region are indicated. The vertical region shaded in red indicates 
the smallest region of overlap (SRO) implicated in ID and seizures from our study; in yellow, 
the  SRO  implicated  in  microcephaly;  in  blue,  the  SRO  implicated  in  corpus  callosum 
abnormalities.  B. Detailed map of the proposed critical  region for ID and seizures,  which 
contains three candidate genes:  HNRNPU,  FAM36A and  NCRNA00201. The  EFCAB2  gene 
was  considered  as  unlikely  causative  since  we have identified  it  in  a  healthy  individual.  
Horizontal  red  bars  indicate  the  deletions  reported  in  the  Database  of  Genomic  Variants 
(www.tcag.org). Three variants involving at least one of the three candidate genes (HNRNPU, 
FAM36A and  NCRNA00201) are reported in the Database of Genomic Variants have been 
identified in three HAPMAP individuals of Yoruba Nigerian origin [Matsuzaki et al., 2009]. 
However, we obtained normal results with our targeted 60K array, excluding a deletion in the 
1q44 region in  these individuals  and,  thus,  demonstrating  that  the  deletions  identified  by 
Matsuzaki et al. [2009] were false positive results.
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Figure 3. Expression patterns of HNRNPU, FAM36A and NCRNA00201 in a panel of human 
tissues.
cDNA  were  obtained  using  the  MMLV  reverse  transcriptase  (Invitrogen)  with  random 
primers from 1 µg of human total RNA of five adult and four fetal tissues. Real-time PCR 
was  performed  in  triplicates  using  Takara  SYBR  premix  on  Light  Cycler  480  (Roche 
diagnostics). The ∆∆Ct method was used to assess expression level of three target genes - 
HNRNPU,  FAM36A  and  NCRNA00201 –  relative  to  the  expression  level  of  the  β-actin 
(ACTB) and cyclophilin E (PPIE) housekeeping genes. For a given target gene, the ∆Ct of 
each tissue was compared to the median of the ∆Ct of the 6 tissues analyzed.
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TABLE I. Clinical features and array CGH data of the 11 patients with 1q44 microdeletion
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 Patient 9 Patient 10 Patient 11 Total
Current age (years) 3 10/12 5 1/12 4 6/12 6/12 12 9/12 2 6/12 13 6/12 106/12 17 4 10/12 910/12
Coordinates of the deletions (in Mb using 
hg19 genome build)
243.1-245.4 243.9-246.5 244.3-245.1 244.4-245.3 244.4-245.6 244.5-246.7 244.5-245.4 244.6-246.1 244.7-245.4 244.8-245.5 244.9-246.3
Size of the deletions 1q44 (Mb) 2.26 2.56 0.79 0.90 1.16 2.19 0.89 1.5 0.68 0.63 1.35
Parental inheritance de novo de novo de novo de novo de novo de novo de novo Mother normal,
father NA
de novo de novo de novo 10/11
Distinctive facial features
hypertelorism - + - - + + + NA - - - 4/10
bulbous nose + + + + - - + NA - - - 5/10
long philtrum - - - - - + + NA - + + 4/10
philtrum flat/ absent cupidon bows + - - - + + - NA + - + 5/10
thick lips + - - + - + - NA - - + 4/10
abnormal ears - - - + + - - NA - + + 4/10
flat occiput - + - - - - - NA - + + 3/10
Measurement abnormalities (SD)
IUGR birth weight -2 -1 -2 +1 NA 0 0 -1 -1,5 -0,5 +0,5
postnatal growth delay -1 -3 -3 -1 -1,8 -2,5 -0,5 -1,5 0 -2,5 -0,8
OFC -4 -3 -2,6 -1 -0,5 -1,2 -1 1,5 0 0 -1
BMI +1 +4 +3 NA +4 +0,5 +1,5 +3,5 +1,8 +4 +4
small fingers and/or toes - + + - + + - - - + + 6/11
Strabismus - NA + NA + - - - + + NA 4/8
Developmental delay/mental retardation severe severe severe severe severe moderate severe moderate to 
severe
severe severe severe
age of the sitted station (years) 3 NA NA NA NA 6/12 10/12 11/12 10/12 NA 10/12
age of walk not acquired 5 (with support ) 3 10/12 NA 3 10/12 2 1 9/12 1 10/12 2 4 10/12 2
no expressive speech + - + NA - - + - + - + 5/10
hypotonia + NA + - - + - - + NA - 4/9
stereotyped movements of the hands + - + - - - + - + + - 5/11
sleep disorders - NA - NA - - - - + + - 2/9
autistic features and/or attention deficit 
disorders
- NA - NA - - + - + + + 4/9
Epileptic seizures + + + + + + + + + + + 11/11
Cerebral MRI generalised 
atrophy, 
moderate 
micropolygyria
micropolygyria, 
delayed 
myelinisation
normal Myelinisation 
delay and 
generalised 
atrophy
normal small-sized 
frontal angioma
Cerebellar 
hypoplasia
moderate 
cerebellar 
hypoplasia
delayed 
myelinisation, 
moderate 
subcortical 
atrophy
normal moderate 
ventricular 
dilatation
corpus callosum normal agenesis normal normal normal normal normal normal normal normal normal
Other features and malformations spaced teeth, 
sparse hair, 
vertical striated 
nails
cardiopathy, 
scoliosis, dry 
skin, articular 
hyperlaxity
articular 
hyperlaxity
cryptorchidy, 
mild nail 
hypoplasia 
fingers
operated talipes 
valgus and flat 
feet
clinodactyly of 
fifth fingers, 
butterfly 
vertebra
erythroderma cryptorchidy genu valgum, 
valgus and flat 
feet, 
hyperlordosis, 
articular 
hyperlaxity
right renal 
agenesis
Supplementary TABLE I. Boundaries and sizes of the deletions identified by array CGH
Patient ID Last centromeric normal probe First centromeric deleted probe Last telomeric deleted probe First telomeric normal probe Size of the deletions
 
Agilent probe 
number
Genomic 
position
Agilent probe 
number
Genomic 
position
Agilent probe 
number
 Genomic 
position
Agilent probe 
number
Genomic 
position
minimum 
size
maximum 
size
1 A_18_P10580799
chr1:24312716
2-243127221 A_18_P18165872
chr1:24316902
8-243169078 A_16_P15516910
chr1:24542780
9-245427868 A_16_P56350629
chr1:245428632-
245428691 2258840 2301470
2 A_18_P18170199
chr1:24398142
9-243981487 A_16_P56348234
chr1:24398165
7-243981707 A_18_P18179048
chr1:24655035
8-246550417 A_16_P563519972
chr1:246550861-
246550920 2568760 2569433
3 A_16_P15514696
chr1:24436896
8-244369027 A_16_P00291606
chr1:24436904
0-244369093 A_16_P00292517
chr1:24516281
5-245162874 A_16_P15516265
chr1:245162911-
245162970 793834 793943
4 A_16_P00291762
chr1:24446357
1-244463630 A_18_P18170664
chr1:24446364
4-244463696 A_16_P563500560
chr1:24537234
8-245372405 A_18_P18173616
chr1:245373000-
245373057 908709 909427
5 A_18_P181717703
chr1:24446311
2-244463156 A_18_P18171183
chr1:24446348
3-244463537 A_16_P00293234
chr1:24562809
6-245628148 A_18_P10584150
chr1:245628202-
245628246 1164665 1165090
6 A_16_P15515033
chr1:24451166
4-244511723 A_16_P00291804
chr1:24451217
9-244512226 A_16_P00294898
chr1:24670789
3-246707952 A_16_P15520201
chr1:246707983-
247708042 2195773 2196319
7 A_16_P00291835
chr1:24453568
7-244535746 A_16_P15515090
chr1:24453604
1-244536093 A_16_P56350678
chr1:24546638
1-245466440 A_16_P15516988
chr1:245466879-
245466938 891827 931192
8 A_16_P56349373
chr1:24466880
2-244668861 A_16_P15515367
chr1:24466987
5-244669934 A_18_P10586547
chr1:24617294
8-246173007 A_16_P35539723
chr1:246173423-
246173482 1503132 1504562
9 A_16_P00292062
chr1:24476487
7-244764926 A_16_P00292063
chr1:24476533
0-244765375 A_16_P56350651
chr1:24544326
2-245443321 A_16_P15516929
chr1:245446121-
245446180 677991 681244
10 A_18_P181724450
chr1:24489098
3-244891027 A_18_P18172462
chr1:24489111
7-244891162 A_18_P18175051
chr1:24552646
9-245527024 A_16_P15517164
chr1:245527049-
245527100 635907 636022
11 A_16_P56350022
chr1:24497457
8-244974632 A_16_P56350024
chr1:24497472
1-244974774 A_18_P10588331
chr1:24633261
0-246332669 A_18_P18177727
chr1:246332753-
246332812 1357948 1358234
CNP A_18_P18171833
chr1:24519752
2-245197581 A_16_P56350270
chr1:24519752
2-245197581 A_16_P15517963
chr1:24582342
0-245823479 A_16_P15517964
chr1:245823589-
245823648 625957 626008



